Long-term Outcomes of Ablation, Liver Resection, and Liver Transplant as First-line Treatment for Solitary HCC of 3 cm or Less Using an Intention-to-treat Analysis: a Retrospective Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 119
- 主要终点
- Intention-to-treat (ITT) overall survival
研究概览
简要总结
Curative-intent therapies for hepatocellular carcinoma (HCC) include radiofrequency ablation (RFA), liver resection (LR), and liver transplantation (LT). Controversy exists in treatment selection for early-stage tumors. We sought to evaluate the oncologic outcomes of patients who received either RFA, LR, or LT as first-line treatment for solitary HCC ≤ 3cm in an intention-to-treat analysis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult (≥18 years) patients
- •Solitary HCC ≤ 3cm
- •Receipt of either radiofrequency ablation, liver resection, or listing for a liver transplant
- •Treatment received between Feb-2000 and Nov-2018
排除标准
- •Pathology other than hepatocellular carcinoma (HCC)
- •Receipt of prior treatment (i.e., not treatment naive)
- •Not eligible for all of the three treatments (ablation, liver resection, or liver transplant listing)
- •Platelet count <100,000 before treatment
- •Alpha-1 fetoprotein (AFP) level > 1000 before treatment
- •Age > 70 years
- •Child-Pugh score C
- •Esophageal varices grade greater than 2
- •Model for End-stage Liver Disease (MELD) score before treatment exceeding 15
- •Presence of ascites pretreatment
- •Presence of encephalopathy pretreatment
- •Spleen size greater than 12 cm
结局指标
主要结局
Intention-to-treat (ITT) overall survival
时间窗: Overall (median length of follow up of entire cohort 6.6 years)
ITT was evaluated from the first treatment modality that was selected for curative intent. In the case of RFA and LR this was recorded as the time of the treatment. In the case of LT, the intention-to-treat was recorded at the time of listing for transplantation. The ITT analysis thus accounted for patients who were placed on the waitlist but dropped out.
Disease-free survival (DFS).
时间窗: Overall (median length of follow up of entire cohort 6.6 years)
DFS was defined as the time after treatment during which the patient was alive and free of disease. For DFS, patients were censored at recurrence, death, or loss to follow up.
次要结局
未报告次要终点